Literature DB >> 17881401

The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines.

Marianne de Sèze1, Alain Ruffion, Pierre Denys, Pierre-Alain Joseph, Brigitte Perrouin-Verbe.   

Abstract

Vesicourethral dysfunction is very frequent in multiple sclerosis (MS) and has functional consequences for patients' quality of life and also an organic impact following complications of the neurogenic bladder on the upper urinary tract. While the functional impact and its management are well documented in the literature, the organic impact remains underestimated and there are no consensual practical guidelines for the screening and prevention of MS neurogenic bladder complications. The aim of this review of the literature, focused on identifying the risk factors of urinary tract complications in MS, is to put forward well informed considerations to help in the definition of practical guidelines for the follow-up of the neurogenic bladder in MS in order to improve its prevention and patient management. Four main risk factors have been identified for upper urinary tract damage: the duration of MS, the presence of an indwelling catheter, high-amplitude neurogenic detrusor contractions and permanent high detrusor pressure. Detrusor-sphincter dyssynergia, age over 50 and male sex may form three additional risk factors. Recommendations for long-term urological follow-up, taking into account these specific risks are constructed according to the procedures recommended by the French Health Authorities.

Entities:  

Mesh:

Year:  2007        PMID: 17881401     DOI: 10.1177/1352458506075651

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  81 in total

1.  Metaboreflex activity in multiple sclerosis patients.

Authors:  Elisabetta Marongiu; Sergio Olla; Sara Magnani; Girolamo Palazzolo; Irene Sanna; Filippo Tocco; Maura Marcelli; Andrea Loi; Francesco Corona; Gabriele Mulliri; Alberto Concu; Antonio Crisafulli
Journal:  Eur J Appl Physiol       Date:  2015-10-01       Impact factor: 3.078

2.  The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.

Authors:  Bhupendra O Khatri; John F Foley; Jennifer Fink; John F Kramer; Choon Cha; Xiaojun You; John D Warth; Pam Foulds
Journal:  Int J MS Care       Date:  2014

3.  Nocturia in Patients With Multiple Sclerosis.

Authors:  Benoit Peyronnet; Lauren B Krupp; W Stuart Reynolds; Xavier Gamé; Gérard Amarenco; Jean-Nicolas Cornu; Lana Zhovtis Ryerson; Carrie Lyn Sammarco; Jonathan E Howard; Robert W Charlson; Roger R Dmochowski; Benjamin M Brucker
Journal:  Rev Urol       Date:  2019

Review 4.  Vesicourethral dysfunction in multiple sclerosis. Initial assessment based on lower urinary tract symptoms and their pathophysiology.

Authors:  Paolo Di Benedetto; Cristina Delneri; Emanuele Biasutti; Luisa Monti Bragadin; Tullio Giorgini
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

5.  Overactive bladder symptoms in patients with multiple sclerosis: Frequency, severity, diagnosis and treatment.

Authors:  Yeşim Akkoç; Murat Ersöz; Nur Yüceyar; Hakan Tunç; Kurtuluş Köklü; Tahir Kurtuluş Yoldaş; Ülkü Dönmez; Cihat Uzunköprü; Ebru Alemdaroğlu; Şule Bilen; Ufuk Emre; Şenay Özdolap; Elif Tuncay; Canan Yücesan; Haydar Gök; Merve Bahar Ercan; Kürşat Uygunol; Belgin Koçer; Murat Zinnuroğlu
Journal:  J Spinal Cord Med       Date:  2016-02-15       Impact factor: 1.985

6.  Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study.

Authors:  Christian Ritter; Martin K R Svačina; Ilja Bobylev; Abhijeet Joshi; Toni Schneider; Helmar C Lehmann
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-01       Impact factor: 4.147

Review 7.  Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Authors:  Oussama El Yazami Adli; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

8.  Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients.

Authors:  Jack Burks; Michael Chancellor; David Bates; Pierre Denys; Scott Macdiarmid; Victor Nitti; Denise Globe; Manuel Signori; Stacie Hudgens; Ib Odderson; Jalesh Panicker; Amy Perrin Ross
Journal:  Int J MS Care       Date:  2013

Review 9.  Neurogenic lower urinary tract dysfunction in multiple sclerosis, neuromyelitis optica, and related disorders.

Authors:  Ryuji Sakakibara
Journal:  Clin Auton Res       Date:  2018-08-03       Impact factor: 4.435

10.  Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances.

Authors:  A Ghezzi; E Mutta; F Bianchi; S Bonavita; F Buttari; A Caramma; R Cavarretta; D Centonze; G C Coghe; G Coniglio; U Del Carro; M T Ferrò; M G Marrosu; F Patti; M Rovaris; M Sparaco; I Simone; C Tortorella; R Bergamaschi
Journal:  Neurol Sci       Date:  2015-11-27       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.